myeloid leukemia Articles
-
Near-atomic-level Details of Cancer Proteins with the Help of Molecular Cages Revealed
Sandwiching the wobble protein between two other layers allowed scientists to get the most detailed picture of a protein that is key to the spread of acute myeloid leukemia. Acute myeloid leukemia (AML) afflicts more than 20,000 Americans each year, killing more than 11,000 of them, according to the American Cancer Institute. And many people who receive intensive chemotherapy or stem cell ...
-
Everything You Want to Know About Pharmacophore Model Construction
Structure-based Pharmacophore Molecular docking technology remains the most popular structure-based drug design method, which takes full advantage of protein-ligand interaction information. However, in virtual screening, compared with molecular docking, pharmacophore-based methods have obvious advantages in terms of computational cost and accuracy, and docking-based virtual screening methods ...
-
Protein Acetylation and Ubiquitination Interactions Control MCL1 Protein Stability
The anti-apoptotic myeloid cell leukemia 1 (MCL1) protein belongs to the BCL2 family that supports survival and is frequently amplified or upregulated in human cancers. MCL1 is highly unstable and its stability is regulated by phosphorylation and ubiquitination. Here, the authors suggest that acetylation is another key post-translational modification that regulates MCL1 protein instability. The ...
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ...
-
Persistent gene editing therapy using LNP-delivered mRNAs
Gene editing technology, represented by CRISPR/Cas9, has greatly accelerated the development of gene therapy, bringing hope to many genetic diseases that otherwise had no cure. In June 2021, Intellia Therapeutics' NTLA-2001, a CRISPR gene editing therapy for the treatment of transthyretin amyloidosis (ATTR) invented by Nobel Laureate Jennifer Doudna, was proven to be safe and effective in a ...
-
What are the ADC drugs?
Antibody-drug conjugates (ADCs) continue to rise at home and abroad, but ADCs are not a new thing. Why has ADC been surging for so many years? What kind of magic power it contains, and what makes its growth path so tortuous? Let's take a brief look at the magical "magic bullet"-ADC. ADC (antibody-conjugated drug) is not a new concept. As early as the early 20th century, the Nobel Prize winner ...
By BOC Sciences
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
-
Antibody Drug Conjugates: "Biological Missiles" For Targeting Cancer Therapy
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
-
Protein Quantification Techniques and Their Application in Clinical Research
Representing the expression, post-translational modification, and protein-protein interaction for certain cells, tissues, or organs, proteomics has become an increasingly important means to understand the molecular mechanism and signal transduction of human disease and cancer. Protein levels in the body are in a steady state of equilibrium. Accumulation of proteins usually leads to qualitative ...
-
How to Design a Good ADC Drug
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
By BOC Sciences
-
Proteomics and the development of precision medicines against cancer (Part 1)
Cancer is a heterogenous mixture of diseases characterized by, among other things, the abnormal, uncontrolled growth of cells derived from otherwise healthy tissues (Hanahan 2022). Although cancer cells sometimes grow into balls of cells and stop there (so-called benign tumors), often they gain the ability to disperse throughout the body, seed the growth of other tumors, disrupt the function of a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you